Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Follow-Up Questions
Quelle est la performance du prix de l'action VINC ?
Le prix actuel de VINC est de $0.04, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Vincerx Pharma Inc ?
Vincerx Pharma Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Vincerx Pharma Inc ?
La capitalisation boursière actuelle de Vincerx Pharma Inc est de $209.2K
Est-ce que Vincerx Pharma Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Vincerx Pharma Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
